Visionary Holdings enters product, technology licensing agreement with Yike

Visionary Holdings (GV) entered into a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine. The agreement grants GV the worldwide rights to apply Yike’s stem cell technology, which has demonstrated significant potential in advancing treatments for diabetes and with other regenerative medicine innovations. Under the agreement, GV is authorized to utilize Yike’s proprietary regenerative medicine technology platform and jointly advance the commercialization and clinical application of related products. The collaboration will focus on key areas such as stem cell therapy, anti-aging biological repair, and cellular rejuvenation: The core stem cell technology system targeting both Type 1 and Type 2 diabetes has conducted clinical trials and the results demonstrated the potential to achieve long-term remission and even complete cure, representing a significant global breakthrough in regenerative medicine and metabolic disease treatment; Integrated stem cell-based therapeutic technologies targeting for immune diseases and metabolic disorders; Technologies for cell preparation, storage, quality control, and clinical application of stem cells. GV will leverage its international commercialization network, clinical collaboration channels, and operational expertise to introduce and expand the application of these technologies across global market. Under the revenue-sharing arrangement, both parties will share returns based on actual product sales and technology commercialization achievements. Yike will primarily generate revenue from technology licensing and clinical R&D, while GV will benefit from market sales, brand operations, and global business development. Yike will continue to provide scientific leadership and technical support, ensuring the sustained competitiveness and continuous innovation of the joint technology platform.